Is Oxyntomodulin FDA approved?

Oxyntomodulin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Eloralintide administered in research settings?

In research settings, Eloralintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Oxyntomodulin administered in research settings?

In research settings, Oxyntomodulin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Eloralintide vs Oxyntomodulin

Peptide Comparison

Eloralintide vs Oxyntomodulin

Q: What is the difference between Eloralintide and Oxyntomodulin?

Eloralintide: Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying Oxyntomodulin: Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Both are Metabolic peptides.

Eloralintide

LY3841136

Fat LossUnder clinical reviewResearch Only

Half-life: Not published

1 providers listed

Full Eloralintide profile →

Oxyntomodulin

OXM

Fat LossInvestigationalResearch Only

No providers listed yet

Full Oxyntomodulin profile →

Bottom line

Eloralintide carries stronger published evidence (Meta-analysis, 4 key studies) than Oxyntomodulin (RCT, 4); both are research compounds.

Quick Verdict

Eloralintide

Oxyntomodulin

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Eloralintide
More provider options (1 vs 0)	Eloralintide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Eloralintide

Oxyntomodulin

Mechanism Family

Metabolic

Half-life

Not published

—

FDA Status

Under clinical review

investigational

Admin Routes

subcutaneous

subcutaneous, intravenous

Availability

Research Only

Providers

1 listed

None listed

Avail. Notes

Selective amylin receptor agonist by Eli Lilly. Phase 2 complete (The Lancet, Nov 2025; n=263, 48 weeks). Phase 3 ENLIGHTEN programme opened Dec 2025-Feb 2026 across obesity (NCT07321886), type 2 diabetes (NCT07282600), obstructive sleep apnoea (NCT07369011) and knee osteoarthritis (NCT07353931). Not FDA-approved; no application on file; lead primary completion 2028.

—

Research Evidence

Eloralintide

Meta-analysis · 4 key studies · most recent 2026

Oxyntomodulin

RCT · 4 key studies · most recent 2026

Research Citations

Eloralintide

Meta-analysis2026 · Endocrinol Diabetes Metab

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…

RCT2026 · Diabetes Obes Metab

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…

RCT2025 · Lancet

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…

RCT2025 · Mol Metab

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…

Oxyntomodulin

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2005 · Diabetes

Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects

Review2026 · Expert Opin Ther Pat

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity a…

Review2026 · Endocr Rev

Regulators of Appetite in Mammals - Old and New players.

About Eloralintide

Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying

Research Areas

appetite suppressionweight losssatiety signaling

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Research Areas

appetite suppressionenergy expenditurefat oxidation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Eloralintide

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

HbA1cFasting glucoseTSHCalcitoninLipaseeGFRALT/AST

No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.

Oxyntomodulin

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Find Providers

Where to source these peptides

Providers offering

Eloralintide

1 listed

Browse directory →

Providers offering

Oxyntomodulin

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.